Chongqing Zhifei Biological Products (300122.SZ)

Overall impact
C (52)

Commentary

Chongqing Zhifei Biological Products is an average overall performer. With a 'C' rating of 52.4 for overall impact (46th percentile compared to all companies), Chongqing Zhifei Biological Products ranks 129th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 125 others, and ahead of Evolus, Summit Therapeutics, Bausch Health Companies and 22 others. On top material causes for Chongqing Zhifei Biological Products's industry (Pharmaceuticals & Biotech), Chongqing Zhifei Biological Products performs well in Disease Eradication (96.4 score) and Technology Innovation (92.5) and performs poorly in Reduced Waste (29.7 score), Decent, Safe Work Opportunities (36.2), Racial Justice and Civil Rights (30.1) and 5 other causes where it received a 'D' or 'F' score.
Impact
Cause 300122.SZ
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Chongqing Zhifei Biological Products

Employees
6,292
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
China
Share classes
300122.SZ
Description
Chongqing Zhifei Biological Products Co., Ltd. engages in the research, development, manufacture, marketing, distribution, import, and export of vaccines and biological products in China. It also provides cold storage services. The company was founded in 2002 and is based in Chongqing, China.
Material causes
Ethos considers the following causes material for Chongqing Zhifei Biological Products, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.